TherapeuticsMD (NASDAQ:TXMD) Shares Up 12.1% – Time to Buy?

TherapeuticsMD, Inc. (NASDAQ:TXMD)’s share price traded up 12.1% on Tuesday . The stock traded as high as $2.59 and last traded at $2.50. 277,306 shares traded hands during mid-day trading, an increase of 128% from the average session volume of 121,810 shares. The stock had previously closed at $2.23.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings raised TherapeuticsMD from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Monday, January 12th. One research analyst has rated the stock with a Hold rating, Based on data from MarketBeat, the stock currently has an average rating of “Hold”.

TherapeuticsMD Stock Up 12.1%

The stock has a market cap of $28.93 million, a price-to-earnings ratio of -250.00 and a beta of 0.43. The company’s 50-day simple moving average is $1.79 and its 200-day simple moving average is $1.37.

TherapeuticsMD (NASDAQ:TXMD) last announced its quarterly earnings data on Wednesday, November 12th. The company reported $0.01 EPS for the quarter. The company had revenue of $0.78 million during the quarter. TherapeuticsMD had a return on equity of 0.27% and a net margin of 10.80%.

Hedge Funds Weigh In On TherapeuticsMD

An institutional investor recently raised its position in TherapeuticsMD stock. Citadel Advisors LLC boosted its stake in shares of TherapeuticsMD, Inc. (NASDAQ:TXMD) by 125.5% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 34,273 shares of the company’s stock after buying an additional 19,073 shares during the period. Citadel Advisors LLC owned about 0.30% of TherapeuticsMD worth $36,000 at the end of the most recent reporting period. 30.74% of the stock is owned by institutional investors.

About TherapeuticsMD

TherapeuticsMD, Inc (NASDAQ:TXMD) is a women’s healthcare company dedicated to the development and commercialization of hormone therapy and contraceptive products. The company’s primary focus lies in addressing unmet needs in menopause management and birth control by offering innovative, non-estrogen alternatives designed to improve patient convenience and adherence. TherapeuticsMD operates in the United States, serving women through a specialty care distribution network that includes physician practices, clinics and pharmacies.

Among its flagship products is IMVEXXY, an FDA-approved low-dose vaginal estradiol insert indicated for the treatment of moderate to severe dyspareunia due to menopause.